Self Directed Investor News » oncologic http://www.selfdirectedinvestornews.com Thu, 09 Sep 2010 06:40:32 +0000 http://wordpress.org/?v=2.8.4 en hourly 1 FDA Approval for GlaxoSmithKline – Analyst Blog http://www.selfdirectedinvestornews.com/financialinvesting/alternative-investing/fda-approval-for-glaxosmithkline-%e2%80%93-analyst-blog/ http://www.selfdirectedinvestornews.com/financialinvesting/alternative-investing/fda-approval-for-glaxosmithkline-%e2%80%93-analyst-blog/#comments Wed, 21 Oct 2009 19:53:14 +0000 Self Directed News http://www.selfdirectedinvestornews.com/sdin/fda-approval-for-glaxosmithkline-%e2%80%93-analyst-blog/ Yesterday, GlaxoSmithKline ( GSK ) received some good news with the US Food and Drug Administration’s (FDA) approval of Votrient (pazopanib) for the treatment of patients with advanced renal cell carcinoma (RCC), a form of kidney cancer. However, the FDA approval does not come as a surprise to us as earlier this month the FDA’s Oncologic Drugs Advisory Committee (ODAC) had voted unanimously in favor of the drug.  The favorable recommendation was based on encouraging results from a phase III

Here is the original post:
FDA Approval for GlaxoSmithKline – Analyst Blog

]]> http://www.selfdirectedinvestornews.com/financialinvesting/alternative-investing/fda-approval-for-glaxosmithkline-%e2%80%93-analyst-blog/feed/ 0 FDA Panel Backs Glaxo’s Votrient – Analyst Blog http://www.selfdirectedinvestornews.com/financialinvesting/alternative-investing/fda-panel-backs-glaxo%e2%80%99s-votrient-%e2%80%93-analyst-blog/ http://www.selfdirectedinvestornews.com/financialinvesting/alternative-investing/fda-panel-backs-glaxo%e2%80%99s-votrient-%e2%80%93-analyst-blog/#comments Tue, 06 Oct 2009 21:20:00 +0000 Self Directed News http://www.selfdirectedinvestornews.com/sdin/fda-panel-backs-glaxo%e2%80%99s-votrient-%e2%80%93-analyst-blog/ GlaxoSmithKline ( GSK ) received positive news yesterday when the US Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee (ODAC) voted unanimously in favor of the company’s experimental kidney cancer drug, Votrient (pazopanib). Importantly, the panel voted that Votrient can benefit patients by slowing the disease, despite some risk of liver damage. We believe the company may be asked to submit data from ongoing studies to ensure that liver toxicity associated with the use o

Read more:
FDA Panel Backs Glaxo’s Votrient – Analyst Blog

]]> http://www.selfdirectedinvestornews.com/financialinvesting/alternative-investing/fda-panel-backs-glaxo%e2%80%99s-votrient-%e2%80%93-analyst-blog/feed/ 0